PMC5712115_01
Chest CT scans. Left panel shows an interstitial infiltrate previous to ruxolitinib. Right panel shows 1-month chest CT scan follow-up with nearly complete resolution of the pulmonary infiltrates
40164_2017_92_Fig1_HTML.jpg
PMC5712115_01_40164_2017_92_Fig1_HTML.jpg
Fig1
After 12 months of treatment the patient have normal lung function and no other signs of GVHD nor leukemia relapse (Fig. 1).
PMC5712115_02
Left panel shows colonoscopy with erythema and inflammation of duodenum. Right panel show a complete resolution of GVHD, 4 weeks after Ruxolitinib
40164_2017_92_Fig2_HTML.jpg
PMC5712115_02_40164_2017_92_Fig2_HTML.jpg
Fig2
Endoscopic duodenal biopsy showed a severe GVHD NIH grade 3 (Fig. 2).
PMC5712115_03
a Erythroderma at diagnosis of aGVHD. b Regression of cutaneous aGVHD after 2 weeks of treatment with ruxolitinib
40164_2017_92_Fig3_HTML.jpg
PMC5712115_03_40164_2017_92_Fig3_HTML.jpg
Fig3
One month later a second DLI of 1 x 106 CD3/kg was performed, which resulted in severe erythroderma with mucosal involvement (Fig. 3).
PMC5712115_04
a Several mucosal lesions compatibles with mucocele. b A nearly complete remission of mucoceles, after treatment with ruxolitinib
40164_2017_92_Fig4_HTML.jpg
PMC5712115_04_40164_2017_92_Fig4_HTML.jpg
Fig4
Ruxolitinib 10 mg QD was initiated and after 2 months of treatment the liver tests returned to normal and the oral lesions partially remitted allowing her to satisfactory feeding (Fig. 4).
PMC5712115_05
PMC5712115_06
Left panels show intense sclerotic features of cGVHD in hands and neck. Right panel shows some improvement in hands and nearly complete resolution in neck after ruxolitinib treatment
40164_2017_92_Fig5_HTML.jpg
PMC5712115_06_40164_2017_92_Fig5_HTML.jpg
Fig5
Modified Rodnan score improved from 26 to 16 (Fig. 5).
PMC5712115_07
Left panels show intense sclerotic features of cGVHD in both hands and feet. Right panel shows a nearly complete resolution after ruxolitinib treatment
40164_2017_92_Fig6_HTML.jpg
PMC5712115_07_40164_2017_92_Fig6_HTML.jpg
Fig6
After 6 months of treatment he shows a significant improvement of scleroderma, he recovered his basal weight and shows a complete improvement of ocular GVHD (Fig. 6).
PMC5712115_08
Left Pannel shows CT Scan at diagnosis of chronic lung GVHD. Right panel shows CT scan 3 months after ruxolitinb treatment
40164_2017_92_Fig7_HTML.jpg
PMC5712115_08_40164_2017_92_Fig7_HTML.jpg
Fig7
Ruxolitinib 10 mg BID was started and after 3 months of therapy his CT Scan showed a complete remission of lung nodular infiltrates (Fig. 7).